Pruitt K
Texas Tech University Health Sciences Center, Lubbock, TX, United States.
Prog Mol Biol Transl Sci. 2016;144:3-47. doi: 10.1016/bs.pmbts.2016.09.001. Epub 2016 Oct 7.
Tumorigenesis is a complex process that involves a persistent dismantling of cellular safeguards and checkpoints. These molecular and cellular changes that accumulate over months or decades lead to a change in the fundamental identity of a cell as it transitions from normal to malignant. In this chapter, we will examine some of the molecular changes in the evolving relationship between the genome and epigenome and highlight some of the key changes that occur as normal cells progress to tumor cells. For many years tumorigenesis was almost exclusively attributed to mutations in protein-coding genes. This notion that mutations in protein-coding genes were a fundamental driver of tumorigenesis enabled the development of several novel therapeutics that targeted the mutant protein or overactive pathway responsible for driving a significant portion of the tumor growth. However, because many therapeutic challenges remained in the face of these advances, it was clear that other pieces to the puzzle had yet to be discovered. Advances in molecular and genomics techniques continued and the study of epigenetics began to expand and helped reshape the view that drivers of tumorigenesis extended beyond mutations in protein-coding genes. Studies in the field of epigenetics began to identify aberrant epigenetic marks which created altered chromatin structures and enabled protein expression in tissues that defied rules governing tissue-specificity. Not only were epigenetic alterations found to enable overexpression of proto-oncogenes, they also led to the silencing of tumor suppressor genes. With these discoveries, it became clear that tumor growth could be stimulated by much more than mutations in protein-coding genes. In fact, it became increasingly clear that much of the human genome, while transcribed, did not lead to proteins. This discovery further led to studies that began to uncover the role of noncoding RNAs in regulating chromatin structure, gene transcription, and tumor biology. In this chapter, some of the key alterations in the genome and epigenome will be explored, and some of the cancer therapies that were developed as a result of these discoveries will be discussed.
肿瘤发生是一个复杂的过程,涉及对细胞保护机制和检查点的持续破坏。这些在数月或数十年间积累的分子和细胞变化,导致细胞从正常状态转变为恶性状态时其基本特性发生改变。在本章中,我们将研究基因组与表观基因组之间不断演变的关系中的一些分子变化,并重点介绍正常细胞发展为肿瘤细胞时发生的一些关键变化。多年来,肿瘤发生几乎完全归因于蛋白质编码基因的突变。这种认为蛋白质编码基因突变是肿瘤发生的根本驱动因素的观念,推动了几种新型疗法的开发,这些疗法靶向负责驱动大部分肿瘤生长的突变蛋白或过度活跃的信号通路。然而,尽管有这些进展,但面对许多治疗挑战,显然还有其他拼图碎片有待发现。分子和基因组技术不断进步,表观遗传学研究开始扩展,并有助于重塑肿瘤发生驱动因素不仅限于蛋白质编码基因突变的观点。表观遗传学领域的研究开始识别异常的表观遗传标记,这些标记会导致染色质结构改变,并使蛋白质在违背组织特异性规则的组织中表达。不仅发现表观遗传改变会导致原癌基因过度表达,还会导致肿瘤抑制基因沉默。有了这些发现,很明显肿瘤生长不仅仅受蛋白质编码基因突变的刺激。事实上,越来越清楚的是,人类基因组的很大一部分虽然会转录,但不会产生蛋白质。这一发现进一步引发了一些研究,这些研究开始揭示非编码RNA在调节染色质结构、基因转录和肿瘤生物学中的作用。在本章中,我们将探讨基因组和表观基因组中的一些关键改变,并讨论基于这些发现开发的一些癌症治疗方法。